The BRAIN Foundation Synchrony 2022 December 2 - 4 | 4141 Hacienda Dr, Pleasanton REGISTER NOW AGENDA
9:30 AM - 6:00 PM PST

December 2, 2022 - Roundtables

9:30 AM - 6:00 PM PST

Track 1

9:30 AM - 12:00 PM

NeuroInflammation - Working Group to create consensus article *2.5 AMA PRA Category 1 Credits™

Session Chair

Jennifer Frankovich, MD, MS

Clinical Professor, Dept of Pediatrics, Stanford Children’s Health
Lucile Packard Children’s Hospital Stanford

PANEL:
Elizabeth D. Mellins, MD, Stanford University
Harumi Jyonouchi, PhD, St. Peter’s University Hospital
Stephen J. Walker, PhD, Wake Forest Institute for Regenerative Medicine

9:30 AM - 6:00 PM PST

Track 2

9:30 AM - 12:00 PM

Pathways to FDA Approval - Challenges and Guidance

Session Chair

Gabriel Belfort, MD, PhD

Vice President, Clinical Development Sciences, Axial Therapeutics Inc.

PANEL:
Gabriel Belfort MD, PhD, Axial Therapeutics,
Kevin Sanders MD, Roche/Genentech
Gahan Pandina PhD, Janssen Research and Development
Robert H. Ring PhD, Kaerus Bioscience Ltd.
John Slattery, BioROSA Technologies
Joanna Sambor, MS, VP and Head of Regulatory at MapLight Therapeutics

12:00 PM - 4:00 PM

Pre-conference Outing: Livermore Wine Country

4:00 PM - 6:00 PM

Biomarkers to guide diagnosis and treatment

Session Chair

John Slattery

Co-founder, President & CEO, BioROSA

PANEL:
Manish Arora, BDS, MPH, PhD, Icahn School of Medicine at Mount Sinai
Karen J. Parker, PhD, Stanford University
Robert H. Ring, PhD, Kaerus Bioscience Ltd.
Kevin Sanders, MD, Roche/Genentech
Micheal Paul, PhD, MaraBio Systems Inc.

6:30 PM

Dinner: Dosa Party

9:00 AM - 6:00 PM PST

December 3, 2022

Roundtable

9:00 AM - 11:00 AM

Seizures in ASD * 2.0 AMA PRA Category 1 Credits™

Session Chair

Richard Frye, MD, PhD

Neurologist
Phoenix Children’s Hospital and University of Arizona College of Medicine-Phoenix

PANEL:
Samuel Pleasure, MD, PhD, UCSF
James Adams, PhD, Arizona State University,
Manuel Casanova, MD, University of South Carolina
John Gaitanis, MD, Brown University
Jeffrey Lewine, CEO/CSO, Center for Advanced Diagnostics, Evaluation and Therapeutics

10:00 AM - 12:30 PM PST

Research Presentations

10:00 AM - 10:20 AM

Randy Blakely, PhD

Executive Director,
Stiles-Nicholson Brain Institute and Florida Atlantic University College of Medicine

Does a Disrupted, Bidirectional Relationship Between Serotonin and Inflammatory Signaling Support ASD traits? Lessons from Model System Studies

10:20 AM - 10:40 AM

Naveen Nagarajan, PhD

University of Utah

Microglia specific circuit defects in repetitive form of ASD behaviors

10:40 AM - 11:00 AM

Stephen E.P. Smith, PhD

University of Washington

Identification of novel drug targets through the analysis of protein interaction network dysfunction

11:00 AM - 11:10 PM

BREAK

11:10 AM - 11:30 AM

Brittany Needham, PhD

Stark Neurosciences Research Institute, IUSM

Gut microbial metabolites influence the brain and behavior in a preclinical and clinical ASD context

11:30 AM - 11:50 AM

Maude David, PhD

Oregon State University

Multi-omics, microbiome, and behavioral studies show the importance of fatty acids metabolism in Autism Spectrum Disorder

11:50 AM - 12:10 PM

Richard Boles, MD

NeurAbilities Healthcare

High Sensitivity for Monogenic Causal Diagnoses in Autism, Including De Novo Variants Representing Novel Disorders, with Trio Whole Genome Sequencing and Data Reanalysis

12:10 PM - 12:30 PM

Benjamin Marlow, MBiochem, ABPI, MBBS MRCPCH, PGCME

Cognition Health

Building on research success in Alzheimer’s to make an impact in the field of Autism

12:30 PM - 1:30 PM

Mexican Fusion Food Truck

1:30 PM - 4:30 PM PST

Industry Presentations

1:30 PM - 1:45 PM

Sarika Agrawal

Cofounder, The BRAIN Foundation

Changing the Status Quo

1:45 PM - 2:15 PM

Lynn Durham

CEO, Stalicla

Translating Precision Medicine for Neurodevelopmental Disorders

Baltazar Gomez-Mancilla

CMO, Stalicla

Translating Precision Medicine for Neurodevelopmental Disorders

2:15 PM - 2:45 PM

Katya Sverdlov

CEO, Jelikalite

Treating Autism with tPBM, New EEG Evidence

Eugenia Steingold

CSO, Jelikalite

Treating Autism with tPBM, New EEG Evidence

2:45 PM - 3:05 PM

Manish Arora, BDS, MPH, PhD

CEO, Linus Biotechnology Inc.

A Precision Exposome Biomarker Platform for Early Detection and Drug Development in ASD

3:05 AM - 3:25 PM

BREAK

3:25 PM - 3:45 PM

Robert Mills

Director of Science, Precidiag Inc.

Meta-analysis of the autism gut microbiome identifies factors influencing study discrepancies and machine learning classification

3:45 PM - 4:05 PM

Paul Song, MD

Vice Chairman and Senior Advisor at NKGen Biotch

The Regulatory Role of Natural Killer Cells in Neuroinflammation and its Potential Therapeutic Role in ASD

4:05 PM - 4:25 PM

Richard Frye, MD, PhD

Scientific Advisor, Aprofol

Levoleucovorin Treatment for Autism Spectrum Disorder.

6:00 PM - 6:30 PM

COCKTAILS

6:30 PM - 7:00 PM

Sean O’ Sullivan

Kickstarting Promising Research Areas: What High Net-Worth Individuals and Family Foundations can do

7:00 PM

DINNER & LIVE MUSIC

9:00 AM - 5:00 PM PST

December 4, 2022 - Invited Speakers

9:00 AM - 9:15 AM

Pramila Srinivasan, PhD

President & Founder, The BRAIN Foundation

Opening Remarks

9:15 AM - 9:45 AM

Manish Arora, BDS, MPH, PhD

Edith J Baerwald Professor and Vice Chairman of the Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai

Harnessing the exposome to diagnose autism

9:45 AM - 10:15 AM

BREAK

10:15 AM - 10:45 AM

Richard Frye, MD, PhD *0.5 AMA PRA Category 1 Credit™

Neurologist
Phoenix Children’s Hospital and University of Arizona College of Medicine-Phoenix

Update on Mitochondrial Research

10:45 AM - 11:15 AM

T. Atilla Ceranoglu, MD *0.5 AMA PRA Category 1 Credit™

Director, Psychiatry Service, Shriners Hospital for Children Massachusetts Gen. Hospital, Boston, MA

Evaluation of Transcranial Photobiomodulation in Autism spectrum disorder: Double-blind, placebo-controlled, randomized clinical study of a novel approach

11:15 AM - 11:45 AM

John Gaitanis, MD *0.5 AMA PRA Category 1 Credit™

Pediatric Neurologist, Epileptologist, Hasbro Children’s Hospital

Medical Cannabis and Autism

11:45 AM - 12:45 PM

LUNCH

1:00 PM - 1:30 PM

Alessio Fasano, MD *0.5 AMA PRA Category 1 Credit™

Division Chief, Pediatric Gastroenterology and Nutrition
Director, Center for Celiac Research and Treatment
Director, Mucosal Immunology and Biology Research Center, Massachusetts General Hospital for Children

Evaluation of Zonulin Pathway for personalized treatment of Autism spectrum disorder using a humanized mouse model and human intestinal tissue

1:30 PM - 2:00 PM

Arthur Krigsman, MD *0.5 AMA PRA Category 1 Credit™

Pediatric Gastroenterologist
Private Practice, New York

Stephen Walker, PhD *0.5 AMA PRA Category 1 Credit™

Professor, Wake Forest Institute for Regenerative Medicine
Wake Forest School of Medicine

 

Improvement in Gastrointestinal Symptoms, Cognition and Behavior Upon Treatment of ASD- associated Enterocolitis

2:00 PM - 2:30 PM

Joseph D. Buxbaum, PhD *0.5 AMA PRA Category 1 Credit™

Professor of Psychiatry, Neuroscience, Genetics and Genomic Sciences
Icahn School of Medicine at Mount Sinai

From rare mutations to common treatments in ASD

2:30 PM - 3:00 PM

BREAK

3:00 PM - 3:30 PM

James Adams, PhD *0.5 AMA PRA Category 1 Credit™

Arizona State University

Microbiota Transplant for Pitt Hopkins

3:30 PM - 4:00 PM

Harumi Jyonouchi, MD *0.5 AMA PRA Category 1 Credit™

Allergy and Immunology, Saint Peter’s University Hospital

Biomarkers of Innate Immune Memory in Autism Spectrum Disorders

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Consultants and The BRAIN Foundation. CME Consultants is accredited by the ACCME to provide continuing medical education for physicians.

CME Consultants designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.